肾移植受者伴血管病变(Banff cv 评分>2)中贝拉西普挽救性转换的回顾性队列研究
这项双中心回顾性队列研究比较了139例伴组织学血管损伤(cv≥2,g+cpt≤1,i+t≤1)且eGFR≤40 mL/min/1.73 m²的肾移植受者中,将钙调磷酸酶抑制剂(CNI)转换为贝拉西普与继续使用CNI的结局。转换组移植物丢失更少(14.5% vs 37.1%,P=.005),3年移植物存活率更高(84.0% vs 65.1%),但机会性感染风险增加(HR 4.84,P<.005)。
要点
- 贝拉西普转换组移植物丢失10例(14.5%),匹配的CNI继续组26例(37.1%)(P=.005)。
- 转换组3年移植物存活率84.0%,对照组65.1%,死亡删失移植物存活率显著更高(P=.001)。
- 贝拉西普组机会性感染风险独立增加(HR 4.84,P<.005),需谨慎对待。
核心结论
- 在移植肾功能下降且伴血管病变的患者中,以贝拉西普替代CNI与移植物存活改善相关,在器官短缺背景下是有价值的选择。
- 应警惕机会性感染风险增加。
研究设计与样本
- 双中心回顾性队列研究,纳入139例肾移植受者,比较CNI转换为贝拉西普(n=69)与继续CNI(匹配组n=70)。
- 纳入标准为组织学肾脏血管损伤(cv≥2,g+cpt≤1,i+t≤1)且估算肾小球滤过率≤40 mL/min/1.73 m²。
主要发现
- 随访期间贝拉西普组移植物丢失10例(14.5%),匹配CNI组26例(37.1%)(P=.005)。
- 死亡删失移植物存活率在贝拉西普组显著更高(P=.001);3年时贝拉西普组84.0%,对照组65.1%。
- 继续使用CNI是移植物丢失的独立危险因素(HR 3.46;P<.005)。
- 转换后细胞性排斥反应发生率低(两组均为4.3%),组间无显著差异(P=.84)。
- 转换为贝拉西普的患者新发供者特异性抗体显著更少;贝拉西普是机会性感染的独立危险因素(HR 4.84;P<.005)。
临床怎么用
- 作者认为,在移植肾功能下降且伴血管病变的患者中,以贝拉西普替代CNI与移植物存活改善相关,是器官短缺背景下的有价值选择。
- 作者提示应警惕机会性感染风险增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunosuppression in kidney transplant recipients with decreased graft function and histological vascular changes can be particularly challenging. The impact of a late rescue conversion to belatacept on kidney graft survival in this context has never been studied. METHODS: We report a bicentric retrospective cohort study comparing a calcineurin inhibitor (CNI) to belatacept switch versus CNI continuation in 139 kidney transplant recipients with histological kidney vascular damage (cv ≥2, g + cpt ≤1, i + t ≤1) and low estimated glomerular filtration rate (≤40 mL/min/1.73 m²). Primary outcome was death-censored graft survival. RESULTS: During the study follow-up, 10 graft losses (14.5%) occurred in the belatacept group (n = 69) versus 26 (37.1%) in the matched CNI group (n = 70) (P = .005). Death-censored graft survival was significantly higher in the belatacept group (P = .001). At 3 years, graft survival was 84.0% in the belatacept group compared with 65.1% in the control group. Continuing CNI was an independent risk factor for graft loss [hazard ratio (HR) 3.46; P < .005]. The incidence of cellular rejection after the conversion was low (4.3% in both groups) and not significantly different between groups (P = .84). Patients switched to belatacept developed significantly less donor-specific antibodies de novo. Belatacept was an independent risk factor for the occurrence of opportunistic infections (HR 4.84; P < .005). CONCLUSION: The replacement of CNI with belatacept in patients with decreased allograft function and vascular lesions is associated with an improvement in graft survival and represents a valuable option in a context of organ shortage. Caution should be exercised regarding the increased risk of opportunistic infection.
引用
- Bertrand D, Matignon M, Morel A, et al. Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2): a retrospective cohort study. Nephrol Dial Transplant. 2023. PMID: 35544123. doi:10.1093/ndt/gfac178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。